Neoleukin Therapeutics, Inc.

Designer of de novo cytokine mimetics for use as immunotherapies

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019 based on the work of Daniel-Adriano Silva, Umut Yilmaz, Carl Walkey and Alfredo Quijano Rubio. The company is creating next generation immunotherapies using breakthrough de novo protein design technology. Neoleukin’s lead program, NL-201, is the world’s first computationally-designed de novo protein therapeutic. It is positioned as a potential best-in-class IL-2/IL-15 cancer immunotherapy and is planned to enter the clinic in the first half of 2021. The company went public through a reverse merger in August 2019 and trades under the ticker NLTX.